Oral anticoagulant use among Medicare patients newly diagnosed with venous thromboembolism (VTE): Factors associated with treatment status
In this study of Medicare patients newly diagnosed with VTE, half of the patients were not treated with OAC in the first month from initial diagnosis. Factors such as Hispanic ethnicity, having low-income subsidy, and comorbidity burden were found to be associated with being untreated with OAC. Among OAC-treated patients, the majority were treated with DOAC vs. warfarin. Interestingly, more than a third of OAC-treated patients were not treated beyond 3 months, which warrants further investigation.
Authors
- David R. Steffen
- Aolin Wang (ORCID: https://orcid.org/0000-0002-3490-648X)
- Abigail Zion (ORCID: https://orcid.org/0000-0001-6598-394X)
- Robert Stellhorn
- James C. Coons (ORCID: https://orcid.org/0000-0002-7193-3751)
- Dominick Latrémouille-Viau (ORCID: https://orcid.org/0000-0002-8565-9220)
- Feng Dai (ORCID: https://orcid.org/0000-0002-9963-6863)
- Cristina Russ (ORCID: https://orcid.org/0000-0001-7248-9712)
- Dong Cheng (ORCID: https://orcid.org/0009-0002-8689-6719)
- Dionne M. Hines
- Serina Deeba
Institutions
- University of Pittsburgh (US)
- Pfizer (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- UPMC Presbyterian (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1371/journal.pone.0321106
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer